Skip to main content
  • Take a look inside the lifecycle of biotech startup Isoprene

    The UMB startup is working from the New Ventures lab in the BioPark.

    Read more
  • Isoprene Pharmaceuticals awarded a two-year $2 million SBIR Direct-to-Phase II grant

    The UMB startup is developing oral therapeutics for triple negative breast cancer and other cancers.


    Read more
  • Empower Therapeutics developing a simple, reliable brainwave biomarker for pain sensitivity

    The newly launched UMB startup has licensed technology developed by scientists at UMB and the University of Birmingham, U.K.

    Read more
  • Pumas-AI licenses UMB technology, enhancing existing platform

    Pumas-AI, a UMB startup, provides end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development lifecycle.

    Read more
  • CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System

    The UMB med device startup is focused on delivering transformative solutions for minimally-invasive surgery.

    Read more
  • UMB startup Medcura launched a new class of high-performance, antibacterial hemostats

    Rapid-Seal® is available online and through a leading drugstore in the U.S. market.

    Read more
  • COVID-19 Research Operation Updates

    Effective Monday, June 21, 2021 research operations will move a step closer toward normal operations.

    Learn more
  • RNA Disease Diagnostics Licenses Cutting-Edge Molecular RNA Diagnostic Platform Technology

    Developed by Dipanjan Pan, MSc, PhD, and his teams at UMB and UMBC, RNADD plans to use the sensor technology to develop a rapid point-of-care COVID-19 test that is comparable to the gold standard RT-PCR lab diagnostic.

    Read more
  • UM Research Is Top 10 For NSF Higher Education R&D

    With more than $1.1 billion in combined research expenditures, the Baltimore/College Park enterprise placed 14th overall nationally and eighth among all public institutions in Research & Development (R&D) spending.

    Read more
  • Edwards Lifesciences treats first patient with Harpoon System in clinical trial

    The HARPOON system was developed at UMB by James. S. Gammie, MD.

    Learn more

Spotlight on...

UM Ventures has launched a series of initiatives for the Center for Maryland Advanced Ventures, including:

NEW ACCELERATOR: Trajectory Next
Trajectory Next is a 12-week post-accelerator program for digital health, bio-health, and life sciences startups.

The Baltimore Fund
The Baltimore Fund provides financial incentives to companies affiliated with Maryland Public Higher Education Institutions to locate in a network of innovation centers in Baltimore City.

The UMCP Fischell Institute
The UMCP Fischell Institute for Biomedical Devices is opening a satellite location at UMB to accelerate the development of innovative medical devices.

Maryland Momentum Fund
The University System of Maryland created the Maryland Momentum Fund, a $25 million early-stage investment program investing in USM-affiliated companies. The Maryland Momentum Fund is staffed by UM Ventures.

University of Maryland, Baltimore Institute for Clinical and Translational Research
The University of Maryland, Baltimore Institute for Clinical and Translational Research (ICTR) is pleased to announce the first round of UMB ICTR Accelerated Translational Incubator Pilot (ATIP) Grant funding opportunities for 2018-2019.


University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More